Compare CVS Health Corp (CVS) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Toronto-Dominion Bank — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.29B), while Toronto-Dominion Bank trades at $114.14 (market cap $186.61B). The key difference: Toronto-Dominion Bank is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Toronto-Dominion Bank for 84 Days on average.
| CVS | TD | |
|---|---|---|
Market Cap | $112.29B | $186.61B |
Volume | 7,763,676 | 4,056,663 |
Sector | Health | Financials |
52-Week High | $110.60 | $124.80 |
52-Week Low | $70.08 | $78.32 |
Typical Hold Time | 83 Days | 84 Days |
Enterprise Value | $174.64B | $559.39B |
Dividend Yield | 3.03% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
TD stock trades at $113.87, down 3.65% on the day, with bearish technical signals but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.98 exceeding expectations by 13.8%. Recent developments include a $10 billion share buyback program and a $108 billion commitment to Canadian infrastructure. Analyst consensus remains positive with 53% buy ratings and no sell recommendations.
TD presents a mixed investment case with strong profitability metrics (24.9% net margin, 13.6% ROE) offset by bearish technical indicators and volatile cash flow patterns. The stock's current valuation at 17.4x P/E appears reasonable given earnings growth, while the aggressive capital return program signals management confidence. Key risks include interest rate sensitivity and ongoing AML remediation efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
